Who: Monte Rosa Therapeutics/Roche
Roche Bonds With Monte Rosa To Degrade Molecular Glues
Deal Expands Reach Of Protein Degradation Platform
Deal Snapshot: Monte Rosa Therapeutics received $50m up front and may earn more than $2bn in milestone fees from Roche for molecular glue degraders to treat cancer and neurological diseases.
More from Deals
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.